Bone Disease Among Children with Sickle Cell Disease: A Scoping Review of Incidence and Interventions

Overview

Journal J Multidiscip Healthc

Publisher Dove Medical Press

Specialty Health Services

Date 2024 Jul 15

PMID 39006879

Authors

Aep Maulid Mulyana

Windy Rakhmawati

Iqbal Pramukti

Mamat Lukman

Riki Wartakusumah

Henny Suzana Mediani

Affiliations

Soon will be listed here.

Abstract

Background: Children with sickle cell disease (SCD) are more likely to have deficient serum levels of vitamin D for bone metabolism. However, appropriate interventions are essential to prevent its progression and alleviate symptoms.

Purpose: The aim of this study is to determine interventions for managing bone disease in children with SCD.

Methods: This study uses a scoping review. A literature review was conducted using PubMed, CINAHL, ScienceDirect, Scopus, and Google Scholar search engines. The study was eligible for inclusion if it included articles published from 2013 to 2023, full-text, and original study design. Study quality was assessed using the Joanna Briggs Institute (JBI) appraisal tool.

Results: This review identified six studies and 114 children with SCD, including 57 boys (50%) and 57 girls (50%). The majority of SCD types experienced were HbSS (86.84%), HbS-B Thal (7.01%), HbSC (5.27%), and the HbSS Arab-Indian haplotype (0.88%). Bone disease problems that often arise in children with SCD include Avascular Necrosis (AVN) (78.08%), Osteonecrosis of the Femoral Head (ONFH) (18.42%), and other bone problems (3.50%). Meanwhile, four types of intervention findings were used in managing bone disease among children with SCD: 1). Surgical procedures 53 (41.09%) included total hip arthroplasty (THA), Osteotomy, and Multiple epiphyseal drilling with Autologous Bone Marrow Implantation (AMBI); 2). Invasive procedures 67 (51.93%) included intravenous bisphosphonates, hydroxyurea (HU), and core decompression (CD) with bone marrow aspirate concentrate injection: 3). Oral pharmacological or Vitamin D3 (cholecalciferol) 4 (3.10%); 4). Non-pharmacology or physical therapy 5 (3.88%).

Conclusion: Our findings highlight that surgical, invasive, pharmacological, and physical therapy interventions positively impact increasing bone mineral density (BMD) and functional improvement of bone disease among children with SCD. The interventions provided excellent functional outcomes with minimal complications and no life-threatening side effects.

References

Kato G, Piel F, Reid C, Gaston M, Ohene-Frempong K, Krishnamurti L . Sickle cell disease. Nat Rev Dis Primers. 2018; 4:18010. DOI: 10.1038/nrdp.2018.10. View

Levac D, Colquhoun H, OBrien K . Scoping studies: advancing the methodology. Implement Sci. 2010; 5:69. PMC: 2954944. DOI: 10.1186/1748-5908-5-69. View

da Silva Junior G, Daher E, da Rocha F . Osteoarticular involvement in sickle cell disease. Rev Bras Hematol Hemoter. 2012; 34(2):156-64. PMC: 3459393. DOI: 10.5581/1516-8484.20120036. View

Oliveira J, Vicente N, Santos J, Weffort V . [Vitamin D in children and adolescents with sickle cell disease: an integrative review]. Rev Paul Pediatr. 2015; 33(3):350-5. PMC: 4620963. DOI: 10.1016/j.rpped.2014.09.008. View

Itzep N, Jadhav S, Kanne C, Sheehan V . Spontaneous healing of avascular necrosis of the femoral head in sickle cell disease. Am J Hematol. 2019; 94(6):E160-E162. DOI: 10.1002/ajh.25453. View

Kavanagh P, Fasipe T, Wun T . Sickle Cell Disease: A Review. JAMA. 2022; 328(1):57-68. DOI: 10.1001/jama.2022.10233. View

Sukmawati S, Hermayanti Y, Fadlyana E, Mulyana A, Nurhakim F, Mediani H . Supplementation of Prenatal Vitamin D to Prevent Children's Stunting: A Literature Review. Int J Womens Health. 2023; 15:1637-1650. PMC: 10617525. DOI: 10.2147/IJWH.S431616. View

Lee M, Licursi M, McMahon D . Vitamin D deficiency and acute vaso-occlusive complications in children with sickle cell disease. Pediatr Blood Cancer. 2015; 62(4):643-7. DOI: 10.1002/pbc.25399. View

. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016; 388(10053):1545-1602. PMC: 5055577. DOI: 10.1016/S0140-6736(16)31678-6. View

10.

Marti-Carvajal A, Sola I, Agreda-Perez L . Treatment for avascular necrosis of bone in people with sickle cell disease. Cochrane Database Syst Rev. 2019; 12:CD004344. PMC: 6894369. DOI: 10.1002/14651858.CD004344.pub7. View

11.

Daltro G, Fortuna V, de Souza E, Salles M, Carreira A, Meyer R . Efficacy of autologous stem cell-based therapy for osteonecrosis of the femoral head in sickle cell disease: a five-year follow-up study. Stem Cell Res Ther. 2015; 6:110. PMC: 4465459. DOI: 10.1186/s13287-015-0105-2. View

12.

Piccin A, Fleming P, Eakins E, McGovern E, Smith O, McMahon C . Sickle cell disease and dental treatment. J Ir Dent Assoc. 2008; 54(2):75-9. View

13.

Gregoire-Pelchat P, Alos N, Ribault V, Pastore Y, Robitaille N, Mailhot G . Vitamin D Intake and Status of Children With Sickle Cell Disease in Montreal, Canada. J Pediatr Hematol Oncol. 2018; 40(8):e531-e536. DOI: 10.1097/MPH.0000000000001306. View

14.

Selma J, Song H, Rivera C, Douglas S, Akella A, Bollavaram K . Sickle cell disease promotes sex-dependent pathological bone loss through enhanced cathepsin proteolytic activity in mice. Blood Adv. 2021; 6(5):1381-1393. PMC: 8905708. DOI: 10.1182/bloodadvances.2021004615. View

15.

Ceglie G, Di Mauro M, Tarissi de Jacobis I, de Gennaro F, Quaranta M, Baronci C . Gender-Related Differences in Sickle Cell Disease in a Pediatric Cohort: A Single-Center Retrospective Study. Front Mol Biosci. 2019; 6:140. PMC: 6906547. DOI: 10.3389/fmolb.2019.00140. View

16.

Garrido C, Bardon-Cancho E, Fajardo-Sanchez V, Cascon-Perez-Teijon M, Garcia-Morin M, Cela E . Evaluation of the effectiveness of prophylactic oral vitamin D (cholecalciferol) in children with sickle cell disease. Bone. 2020; 133:115228. DOI: 10.1016/j.bone.2020.115228. View

17.

Bell V, Varzakas T, Psaltopoulou T, Fernandes T . Sickle Cell Disease Update: New Treatments and Challenging Nutritional Interventions. Nutrients. 2024; 16(2). PMC: 10820494. DOI: 10.3390/nu16020258. View

18.

Novais E, Sankar W, Wells L, Carry P, Kim Y . Preliminary Results of Multiple Epiphyseal Drilling and Autologous Bone Marrow Implantation for Osteonecrosis of the Femoral Head Secondary to Sickle Cell Disease in Children. J Pediatr Orthop. 2015; 35(8):810-5. DOI: 10.1097/BPO.0000000000000381. View

19.

Valenti M, Matte A, Federti E, Puder M, Anez-Bustillos L, Deiana M . Dietary ω-3 Fatty Acid Supplementation Improves Murine Sickle Cell Bone Disease and Reprograms Adipogenesis. Antioxidants (Basel). 2021; 10(5). PMC: 8158389. DOI: 10.3390/antiox10050799. View

20.

Gatin L, Rogier de Mare A, Mary P, Vialle R, Damsin J . Osteonecrosis of the Femoral Head: A Proposed New Treatment in Homozygous Sickle Cell Disease. Hemoglobin. 2016; 40(1):1-9. DOI: 10.3109/03630269.2015.1092159. View